Pramlintide, an analog of Amylin, has been modified to prevent the formation of fibrils preserving stability and solubility of the peptide and has been approved by the FDA for diabetes treatment but not specifically for obesity. The gene discussed is IAPP; the disease is obesity due to melanocortin 4 receptor deficiency.